Plasma atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) levels increase in
patients with heart failure with the progression of clinical symptoms and with the
deterioration of hemodynamics; consequently, assay methods for these peptides may be
useful in the follow-up of cardiac patients. Non-competitive immunoradiometric assay (IRMA)
methods for ANP or BNP do not generally require preliminary extraction and/or purification
of the plasma sample, and so may be more suitable than competitive immunoradiometric …